Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Defence Therapeutics (OTCQB: DTCFF) will present new scientific data on its Accum technology at the 16th World ADC Conference in San Diego on November 4-5, 2025.
The presentation highlights Accum's role in improving intracellular delivery and endosomal escape for antibody-drug conjugates (ADCs), aiming to enhance potency and reduce off-target toxicity. Company scientists Maxime Parisotto and Mark Lambermon will be available at the poster in the Conference Exhibition Hall, Town & Country Resort, to discuss the results and ongoing R&D.
Defence Therapeutics (OTCQB: DTCFF) presenterà nuovi dati scientifici sulla sua tecnologia Accum alla 16ª World ADC Conference a San Diego il 4-5 novembre 2025.
La presentazione evidenzia il ruolo di Accum nel migliorare la consegna intracellulare e l'escape endosomico per i conjugati anticorpo-droga (ADCs), con l'obiettivo di potenziare l'efficacia e ridurre la tossicità fuori bersaglio. Gli scienziati dell'azienda Maxime Parisotto e Mark Lambermon saranno disponibili al poster nella Conference Exhibition Hall, Town & Country Resort, per discutere i risultati e la ricerca in corso.
Defence Therapeutics (OTCQB: DTCFF) presentará nuevos datos científicos sobre su tecnología Accum en la 16ª World ADC Conference en San Diego los días 4-5 de noviembre de 2025.
La presentación destaca el papel de Accum para mejorar la entrega intracelular y la escape del endosoma de los conjugados anticuerpo-droga (ADCs), con el objetivo de aumentar la potencia y reducir la toxicidad fuera del objetivo. Los científicos de la empresa Maxime Parisotto y Mark Lambermon estarán disponibles en el cartel en la Conference Exhibition Hall, Town & Country Resort, para discutir los resultados y la I+D en curso.
Defence Therapeutics (OTCQB: DTCFF) 는 16번째 World ADC Conference 를 샌디에이고에서 2025년 11월 4-5일 사이에 개최되는 새로운 과학 데이터를 Accum 기술에 대해 발표할 예정입니다.
발표는 항체-약물 결합체(ADC)의 세포 내 전달 및 엔도좀 탈출을 개선하는 Accum의 역할을 강조하며, 효능을 높이고 비표적 독성을 줄이는 것을 목표로 합니다. 회사 과학자 Maxime Parisotto 와 Mark Lambermon 은 결과와 진행 중인 연구개발에 대해 토의하기 위해 Town & Country Resort의 Conference Exhibition Hall에 있는 포스터에서 대기할 것입니다.
Defence Therapeutics (OTCQB: DTCFF) présentera de nouvelles données scientifiques sur sa technologie Accum lors de la 16e World ADC Conference à San Diego les 4-5 novembre 2025.
La présentation met en évidence le rôle d'Accum dans l'amélioration de la livraison intracellulaire et de l'échappement endosomique des conjugués anticorps-médicament (ADC), dans le but d'améliorer la puissance et de réduire la toxicité hors cible. Les scientifiques de l'entreprise, Maxime Parisotto et Mark Lambermon, seront disponibles sur l'affiche dans la Conference Exhibition Hall, Town & Country Resort, pour discuter des résultats et des activités de R&D en cours.
Defence Therapeutics (OTCQB: DTCFF) wird neue wissenschaftliche Daten zu seiner Accum-Technologie auf der 16. World ADC Conference in San Diego am 4.–5. November 2025 vorstellen.
Die Präsentation hebt die Rolle von Accum bei der Verbesserung der intrazellulären Lieferung und des Endosomen-Entkommens für Antikörper-Wirkstoff-Konjugate (ADCs) hervor, mit dem Ziel, die Wirksamkeit zu steigern und Off-Target-Toxizität zu senken. Die Unternehmenswissenschaftler Maxime Parisotto und Mark Lambermon stehen am Poster in der Conference Exhibition Hall, Town & Country Resort, zur Diskussion der Ergebnisse und der laufenden F&E bereit.
Defence Therapeutics (OTCQB: DTCFF) ستقدم بيانات علمية جديدة عن تقنيتها Accum في المؤتمر العالمي السادس عشر لـ ADC في سان دييغو في 4-5 نوفمبر 2025.
تبرز العروض دور Accum في تحسين التوصيل داخل الخلية والهروب من الحويصلات الاندوزومية للمركبات المضادة للجسم-دواء (ADC)، بهدف تعزيز الفعالية وتقليل السمية خارج الهدف. سيكون علماء الشركة ماكسيم باريسويتّو ومارك لامبرمون متاحين على الملصق في قاعة المعرض بمؤتمر Town & Country Resort لمناقشة النتائج والأبحاث التطويرية الجارية.
Defence Therapeutics (OTCQB: DTCFF) 将在圣地亚哥举行的第16届全球ADC大会上于2025年11月4-5日展示其Accum技术的新科研数据。
该报告强调Accum在改善抗体药物偶联物(ADC)的细胞内递送和内体逃逸方面的作用，旨在提高效力并降低离靶毒性。公司科学家 Maxime Parisotto 和 Mark Lambermon 将在大会展览厅的海报展位（Town & Country Resort）现场讨论结果和正在进行的研发工作。
- None.
- None.
Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce that it will present new scientific data highlighting the performance of its Accum® technology in enhancing the efficacy of antibody-drug conjugates (ADCs) at the 16th World ADC Conference in San Diego, CA, USA.
Defence's proprietary Accum® platform is engineered to improve intracellular delivery and endosomal escape of therapeutic payloads, addressing a critical limitation of current ADCs and enabling higher potency with reduced off-target toxicity. The new results to be presented build on a growing body of evidence demonstrating Accum®'s ability to significantly improve the therapeutic index of ADCs.
"These findings further demonstrate how Accum® can unlock the full potential of ADCs by enabling more efficient delivery of their toxic payloads directly into cancer cells," said Maxime Parisotto, Chief Scientific Officer of Defence Therapeutics. "We are excited to share this data with the scientific community and continue advancing our research toward next-generation targeted therapies."
Interested attendees are invited to visit the Defence Therapeutics poster presentation at the Conference Exhibition Hall Town & Country Resort in San Diego, CA, USA on Tuesday and Wednesday November 4-5, 2025, to meet with Defence's CSO Maxime Parisotto, PhD, MBA, and Head of Quality & Operation Mark Lambermon, Phd, to learn more about the company's ongoing research and development efforts.
About World ADC San Diego 2025:
This Global Premier Conference for end-to-end ADC Innovation and Success is the World's longest standing & definitive ADC forum, with 1,400 industry attendees, 170+ world class speakers and unrivalled networking opportunities. Showcasing differentiation across the entire ADC value chain, the 2025 program is built to ensure future ADCs provide a meaningful impact to oncology patients in need.
About Defence:
Defence Therapeutics is a publicly-traded biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271440
FAQ
When will Defence Therapeutics (DTCFF) present at the World ADC Conference?
What data will Defence Therapeutics (DTCFF) share about Accum at the November 2025 ADC conference?
Who from Defence Therapeutics will be available to discuss the Accum data at the conference?
How does Accum technology aim to improve ADCs according to Defence Therapeutics (DTCFF)?
Where can investors or attendees view Defence Therapeutics' poster at the World ADC Conference?
